A New PET/CT Scan Aimed at GPRC5D in Multiple Myeloma and Related Conditions
Tests a GPRC5D-targeted PET/CT scan in adults with multiple myeloma and similar disorders.
Plain-language title generated from the registry record
Registry title: GPRC5D Targeted PET/CT Imaging in Plasma Cell Disorders
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 1
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 80 years old?
Source: NCT07660939, who can take part
Where in China
- Peking University First HospitalBeijing, ChinaTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Peking University First Hospital
- Trial code
- NCT07660939
- Record updated
- 28 September 2026
- Original description
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.Read full original descriptionShow less
A Single-Center, Phase I, Single-Arm Prospective Interventional Study of GPRC5D-Targeted PET/CT Imaging in Patients With Multiple Myeloma and Other Plasma Cell Disorders
This is a prospective, single-center, single-arm Phase I study evaluating GPRC5D-targeted PET/CT imaging in patients with plasma cell disorders, including multiple myeloma.
Participants will undergo GPRC5D-targeted PET/CT, 18F-FDG PET/CT, and 68Ga-BCMA PET/CT within 5 days whenever feasible for head-to-head comparison of lesion detection and disease assessment.
The study aims to evaluate the safety, feasibility, biodistribution, and diagnostic performance of GPRC5D-targeted PET/CT and to compare its imaging characteristics with currently available molecular imaging modalities in plasma cell disorders.
Inclusion: Adults with confirmed or suspected plasma cell disorders, including multiple myeloma; Healthy volunteers eligible for PET/CT imaging may also be enrolled; Availability of recent clinical laboratory results within 1 week prior to imaging, when applicable; Ability to undergo PET/CT imaging procedures; Ability to understand the study requirements and provide written informed consent.
Exclusion: History of other active malignant tumors, unless considered clinically insignificant by the investigator; Any medical or psychiatric condition that, in the investigator's judgment, may interfere with study participation or image interpretation; Pregnant or breastfeeding women; Inability to understand study procedures or comply with imaging examinations.